ANALYSIS: What Would A Teva-Mylan Deal Mean For India?
This article was originally published in PharmAsia News
The situation is still fluid on a possible merger between Teva and Mylan and will likely see a few quick and dramatic turns over the next few weeks. In the event a deal does click, it would have a significant impact on the two firms’ Indian businesses and also Indian generic manufacturers more generally.
You may also be interested in...
Teva announced a proposal to acquire Mylan for $82 per share, or roughly $40 billion, putting Mylan’s independence and a proposal to acquire OTC drug specialist Perrigo in question. Adding to the uncertainty, Perrigo rejected Mylan’s offer after market close.
Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.